Posted by Hombre on January 25, 2011, at 19:21:08
In reply to Re: Antispasmodic/Benzo Stomach Med: What is this?, posted by Hombre on January 25, 2011, at 6:52:33
Scopolamine can act as an antidepressant:
http://www.ncbi.nlm.nih.gov/pubmed/20074703
Biol Psychiatry. 2010 Mar 1;67(5):432-8. Epub 2010 Jan 15.
Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial.Drevets WC, Furey ML.
Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA.
AbstractBACKGROUND: We previously reported that intravenous (IV) scopolamine administration produced rapid and robust antidepressant effects in a sample consisting of both unipolar and bipolar depressives. The present study aimed to replicate this finding in an independent sample limited to unipolar depressives.
METHODS: Outpatients with major depressive disorder (MDD; n = 23; 22 were included in analyses) participated in a double-blind, placebo-controlled, crossover trial. Subjects were randomized into either a P/S or S/P sequence (P = block of three placebo sessions; S = block of three scopolamine sessions; [4.0 microg/kg IV]). Sessions occurred 3 to 5 days apart, such that time spent in each block lasted 1.5 to 2 weeks and the interval between blocks was 3 to 5 days. The Montgomery-Asberg Depression Rating Scale (MADRS) served as the primary outcome measure.
RESULTS: Following the initial block, the group receiving scopolamine first (S/P) showed a 32% reduction in MADRS scores (p < .001), which exceeded the corresponding change of 6.5% under placebo (P/S; p = .009), confirming the a-priori hypothesis. Improvement was significant at the first evaluation that followed scopolamine administration (p = .011). In Block 2, the P/S group showed a 53% reduction in MADRS scores (p = .001) following scopolamine versus placebo, whereas the reduction seen in S/P subjects who received scopolamine during Block 1 persisted as they received placebo during Block 2. Scopolamine induced drowsiness, blurred vision, dry mouth, light-headedness, and reduced blood pressure, which were sufficiently well tolerated that no subject dropped out because of side effects.
CONCLUSIONS: These results replicate previous finding that scopolamine produces a rapid and robust antidepressant response.
And it is apparently rapid in in its action:http://hubpages.com/hub/Scopolamine-ARapidRespondingAntidepressant
poster:Hombre
thread:977792
URL: http://www.dr-bob.org/babble/20110115/msgs/977964.html